Treatment of recurrent paget's disease of the vulva with topical bleomycin

Open Access
Publisher Website
Google Scholar
Abstract
Seven patients with recurrent Paget's disease of the vulva underwent treatment with topical bleomycin (NSC 125066‐Blenoxane®, Bristol Laboratories) ointment. None had an associated invasive carcinoma. Four patients experienced a complete, objective response to this therapy, and one of these has responded completely to treatment of a subsequent recurrence. In two patients the response could not be evaluated. All patients experienced pain in the treated area; one, developed systemic toxicity to bleomycin requiring cessation of therapy. Topical bleomycin appears to benefit selected patients with recurrent Paget's disease of the vulva.